首页|Luteolin protects against myocardial ischemia/reperfusion injury by reducing oxidative stress and apoptosis through the p53 pathway

Luteolin protects against myocardial ischemia/reperfusion injury by reducing oxidative stress and apoptosis through the p53 pathway

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Luteolin protects against myocardial ischemia/reperfusion injury by reducing oxidative stress and apoptosis through the p53 pathway
Objective:Myocardial ischemia/reperfusion injury(MIRI)is an obstacle to the success of cardiac reperfu-sion therapy.This study explores whether luteolin can mitigate MIRI by regulating the p53 signaling pathway.Methods:Model mice were subjected to a temporary surgical ligation of the left anterior descending coronary artery,and administered luteolin.The myocardial infarct size,myocardial enzyme levels,and cardiac function were measured.Latent targets and signaling pathways were screened using network pharmacology and molecular docking.Then,proteins related to the p53 signaling pathway,apoptosis and oxidative stress were measured.Hypoxia/reoxygenation(HR)-incubated HL1 cells were used to val-idate the effects of luteolin in vitro.In addition,a p53 agonist and an inhibitor were used to investigate the mechanism.Results:Luteolin reduced the myocardial infarcted size and myocardial enzymes,and restored cardiac function in MIRI mice.Network pharmacology identified p53 as a hub target.The bioinformatic analyses showed that luteolin had anti-apoptotic and anti-oxidative properties.Additionally,luteolin halted the activation of p53,and prevented both apoptosis and oxidative stress in myocardial tissue in vivo.Furthermore,luteolin inhibited cell apoptosis,JC-1 monomer formation,and reactive oxygen species ele-vation in HR-incubated HL1 cells in vitro.Finally,the p53 agonist NSC319726 downregulated the protec-tive attributes of luteolin in the MIRI mouse model,and both luteolin and the p53 inhibitor pifithrin-αdemonstrated a similar therapeutic effect in the MIRI mice.Conclusion:Luteolin effectively treats MIRI and may ameliorate myocardial damage by regulating apop-tosis and oxidative stress through its targeting of the p53 signaling pathway.

P53 signaling pathwayMyocardial ischemia/reperfusion injuryApoptosisOxidative stressLuteolinNetwork pharmacology

Pan Zhai、Xiao-hu Ouyang、Meng-ling Yang、Lan Lin、Jun-yi Li、Yi-ming Li、Xiang Cheng、Rui Zhu、De-sheng Hu

展开 >

Department of Integrated Traditional Chinese and Western Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China

Department of Critical Care Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,Hubei Province,China

Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China

Hubei Key Laboratory of Biological Targeted Therapy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China

China-Russia Medical Research Center for Stress Immunology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hu

展开 >

P53 signaling pathway Myocardial ischemia/reperfusion injury Apoptosis Oxidative stress Luteolin Network pharmacology

2024

10.1016/j.joim.2024.09.001

结合医学学报(英文版)
上海市中西医结合学会,上海长海医院

结合医学学报(英文版)

CSTPCD
影响因子：0.711
ISSN：2095-4964
年,卷(期)：2024.22(6)